Scientists, Advocates Voice Objections To von Eschenbach’s Conflicts, 2015.
Cancer Leadership Council Letter Calls For Permanent Leadership of NCI and FDA.
Cancer Center Directors to Develop Blueprint for Progress That’s “Honest,” M.D. Anderson’s John Mendelsohn Says.
Also von Eschenbach Role in Industry Program Raises New Concerns of Conflict of Interest.
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation
- FDA’s OCE publishes three final guidances to increase clinical trial enrollment









